These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18303084)

  • 41. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
    Murphy DA; Makonnen S; Lassoued W; Feldman MD; Carter C; Lee WM
    Am J Pathol; 2006 Nov; 169(5):1875-85. PubMed ID: 17071608
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PBI-4050 reduces pulmonary hypertension, lung fibrosis, and right ventricular dysfunction in heart failure.
    Nguyen QT; Nsaibia MJ; Sirois MG; Calderone A; Tardif JC; Fen Shi Y; Ruiz M; Daneault C; Gagnon L; Grouix B; Laurin P; Dupuis J
    Cardiovasc Res; 2020 Jan; 116(1):171-182. PubMed ID: 30753422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
    Ou DL; Shen YC; Yu SL; Chen KF; Yeh PY; Fan HH; Feng WC; Wang CT; Lin LI; Hsu C; Cheng AL
    Cancer Res; 2010 Nov; 70(22):9309-18. PubMed ID: 21062976
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Koch A; Evers BM
    Anticancer Res; 2010 Dec; 30(12):4951-8. PubMed ID: 21187475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
    Spirli C; Morell CM; Locatelli L; Okolicsanyi S; Ferrero C; Kim AK; Fabris L; Fiorotto R; Strazzabosco M
    Hepatology; 2012 Dec; 56(6):2363-74. PubMed ID: 22653837
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
    Yuen JS; Sim MY; Sim HG; Chong TW; Lau WK; Cheng CW; Ong RW; Huynh H
    Int J Oncol; 2012 Aug; 41(2):712-20. PubMed ID: 22641227
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
    Rahmani M; Davis EM; Crabtree TR; Habibi JR; Nguyen TK; Dent P; Grant S
    Mol Cell Biol; 2007 Aug; 27(15):5499-513. PubMed ID: 17548474
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
    Hennenberg M; Trebicka J; Kohistani Z; Stark C; Nischalke HD; Krämer B; Körner C; Klein S; Granzow M; Fischer HP; Heller J; Sauerbruch T
    Lab Invest; 2011 Feb; 91(2):241-51. PubMed ID: 20921950
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
    Yu C; Friday BB; Lai JP; Yang L; Sarkaria J; Kay NE; Carter CA; Roberts LR; Kaufmann SH; Adjei AA
    Mol Cancer Ther; 2006 Sep; 5(9):2378-87. PubMed ID: 16985072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of panax notoginseng saponins injection on the p38MAPK pathway in lung tissue in a rat model of hypoxic pulmonary hypertension.
    Zhao S; Zheng MX; Chen HE; Wu CY; Wang WT
    Chin J Integr Med; 2015 Feb; 21(2):147-51. PubMed ID: 25523598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
    J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
    Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
    Ramakrishnan V; Timm M; Haug JL; Kimlinger TK; Halling T; Wellik LE; Witzig TE; Rajkumar SV; Adjei AA; Kumar S
    Am J Hematol; 2012 Mar; 87(3):277-83. PubMed ID: 22190165
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel inhibitor of inducible nitric oxide synthase, ONO-1714, does not ameliorate hypoxia-induced pulmonary hypertension in rats.
    Jiang BH; Maruyama J; Yokochi A; Mitani Y; Maruyama K
    Lung; 2007; 185(5):303-308. PubMed ID: 17721804
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
    Strumberg D
    Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
    Yang F; Jove V; Buettner R; Xin H; Wu J; Wang Y; Nam S; Xu Y; Ara T; DeClerck YA; Seeger R; Yu H; Jove R
    Cancer Biol Ther; 2012 May; 13(7):534-41. PubMed ID: 22406995
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
    Kumar R; Crouthamel MC; Rominger DH; Gontarek RR; Tummino PJ; Levin RA; King AG
    Br J Cancer; 2009 Nov; 101(10):1717-23. PubMed ID: 19844230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.